Q2 2023
Released Nov 4, 2022, before the open
10-Q filed Nov 4, 2022, 35 days after period end · 0001764013-22-000140
Q2 2023 · 10-Q
Revenue—
Net Income-$47.93M-$47.93M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.41-$0.41 N/M vs Q2 2022N/M vs Q1 2023
Operating Cash Flowderived-$20,186,000N/M
Free Cash Flowderived-$20,217,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2018 |
|---|---|---|---|
| Net Income | -$47.93M | -$37.70M | -$6.35M |
| EPS Diluted | -$0.41 | -$0.35 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR